GlassScriptPhysician profile
Anil K Muddada
NPI 1386877751
$5,330.26
in general payments reported to CMS, 2019-2025
36 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $318 · 2021: $143 · 2022: $1,577 · 2023: $1,276 · 2024: $153 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.28 |
| Education | $247.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $537.31 | 2020-2023 | Acthar |
| Aurinia Pharma U.S., INC. | $497.74 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $446.43 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $422.70 | 2019-2023 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $399.88 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $314.40 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $248.37 | 2025 | |
| Amgen INC. | $234.73 | 2019-2025 | Tavneos, Parsabiv |
| Mallinckrodt Enterprises LLC | $232.21 | 2019 | |
| Opko Pharmaceuticals, LLC | $203.74 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $161.85 | 2022-2023 | Tarpeyo |
| Akebia Therapeutics INC | $158.20 | 2019-2023 | Auryxia |
| Fresenius USA Marketing, INC. | $148.14 | 2019-2025 | Velphoro |
| Daiichi Sankyo INC. | $133.01 | 2019-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $130.81 | 2022-2023 | Gattex |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $126.54 | 2022-2023 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $111.20 | 2019-2023 | Ultomiris |
| Ardelyx, INC. | $102.47 | 2024 | Xphozah 30 Mg |
| Amag Pharmaceuticals, INC. | $67.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $62.86 | 2019 | |
| Novo Nordisk INC | $60.45 | 2025 | Ozempic, Wegovy |
| Medtronic, INC. | $50.38 | 2024 | Symplicity G3 |
| Lundbeck LLC | $44.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.33 | 2022-2023 | Benlysta |
| Shire North American Group INC | $33.91 | 2019 | |
| Travere Therapeutics, INC. | $32.86 | 2022-2025 | Filspari |
| Renalytix Ai, INC. | $31.76 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $30.46 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.05 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.89 | 2019 | |
| Esperion Therapeutics, INC. | $20.32 | 2020 | |
| Nxstage Medical, INC. | $19.80 | 2021 | |
| Horizon Therapeutics Plc | $19.03 | 2020 | |
| Baxter Healthcare | $17.32 | 2019 | |
| Genentech USA, INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Muddada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.